Oblimersen for the treatment of patients with chronic lymphocytic leukemia by Cheson, Bruce D
© 2007 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2007:3(5) 855–870 855
REVIEW
Oblimersen for the treatment of patients 
with chronic lymphocytic leukemia
Bruce D Cheson
Georgetown University Hospital, The 
Lombardi Comprehensive Cancer 
Center, Washington, DC, USA
Correspondence: Bruce D Cheson
Professor of Medicine, Head of 
Hematology, Georgetown University 
Hospital, Lombardi Comprehensive 
Cancer Center, 3800 Reservoir Road, 
NW,  Washington, DC 20007, USA
Tel +1 202 444 7932
Fax +1 202 444 1229
Email bdc4@georgetown.edu
Abstract: Among adults in Western countries, chronic lymphocytic leukemia (CLL) is the 
most prevalent form of leukemia. CLL primarily affects the elderly and may be associated with 
multiple comorbidities. A cure has not been identiﬁ  ed, and new treatment options are needed. 
Expression of Bcl-2 protein is associated with the pathogenesis of CLL and chemotherapy 
resistance. Oblimersen, a Bcl-2 antisense phosphorothioate oligonucleotide, is being evaluated 
in patients with CLL and other cancers; trials through Phase III have been completed. In the set-
ting of relapsed/refractory CLL, single-agent oblimersen demonstrates modest activity, whereas 
the addition of oblimersen to ﬂ  udarabine/cyclophosphamide signiﬁ  cantly improves the rate of 
complete and nodular partial responses; moreover, these responses are durable and associated 
with clinical beneﬁ  t. Oblimersen is more efﬁ  cacious in relapsed rather than refractory patients. 
The side effect proﬁ  le of oblimersen, alone or in combination with standard chemotherapy, 
is favorable compared with currently available chemotherapies. In the ﬁ  rst cycle, an infusion 
reaction with or without tumor lysis syndrome is uncommon, and transient thrombocytopenia 
is observed. Catheter-related complications are associated with the need for continuous intrave-
nous infusion of oblimersen over several days; other routes of administration are under clinical 
investigation. Oblimersen is a promising therapeutic approach for patients with relapsed CLL 
and should be further evaluated in the front-line setting.
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Introduction
Among adults in Western countries, chronic lymphocytic leukemia (CLL) is the most 
commonly diagnosed form of leukemia and the most prevalent form of leukemia. 
More than 15,000 new cases will be reported in 2007 in the United States alone (Jemal 
et al 2007), primarily in middle-aged and elderly adults.
This malignancy is characterized by the progressive accumulation of small mono-
clonal B-cells in the blood, bone marrow, lymph nodes, and spleen with resultant 
organ enlargement. CLL may remain indolent for prolonged periods until patients 
require treatment for associated complications – primarily recurrent infections, ane-
mia, thrombocytopenia, progressive lymphadenopathy or hepatosplenomegaly, and 
disease-related symptoms, such as fever, fatigue, and night sweats. The most frequent 
cause of death is recurrent infection due to the immunodeﬁ  ciency associated with this 
disease (including hypogammaglobulinemia and impaired complement activation) and 
the immunodeﬁ  ciency induced by therapies administered for this disease.
In the front-line setting, patients are typically treated with single-agent ﬂ  udara-
bine or a ﬂ  udarabine-based regimen. In fact, purine nucleosides such as ﬂ  udarabine 
have replaced single-agent alkylating drugs as the treatment of choice for previously 
untreated patients and produce signiﬁ  cantly higher response rates than such com-
bination therapies as CAP or CHOP (Rai et al 2000; Leporrier et al 2001). Recent 
randomized studies have demonstrated that the combination of an alkylating agent Therapeutics and Clinical Risk Management 2007:3(5) 856
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and ﬂ  udarabine signiﬁ  cantly increases the rate of complete 
response (Flinn et al 2004; Eichhorst et al 2006); however, 
such regimens offer no demonstrable improvement in sur-
vival and are associated with increased myelosuppression 
when compared with single-agent ﬂ  udarabine. With the avail-
ability of the monoclonal antibody rituximab, combination 
regimens such as ﬂ  udarabine and rituximab with or without 
cyclophosphamide are becoming the standard of care for 
previously untreated patients with CLL.
Patients who relapse after initial therapy are typically 
treated again with ﬂ  udarabine, administered either alone or 
in combination with other agents, including alkylating agents 
such as cyclophosphamide, monoclonal antibodies such as 
alemtuzumab or rituximab, and anthracyclines. Alemtu-
zumab, however, is increasingly being used in a setting of 
minimal residual disease (O’Brien et al 2003; Wendtner et al 
2004; Moreton et al 2005).
Despite improvements in CLL therapy in the last 15 years 
with the introduction of ﬂ  udarabine and rituximab, improve-
ment in survival has not been prospectively conﬁ  rmed (Byrd 
et al 2005). Treatment is often palliative given the toxicity 
of currently available therapies and the multiple comorbid 
conditions that may affect elderly patients with CLL.
Nonclinical pharmacology
Like other cancers, CLL is characterized, in part, by the 
failure of apoptotic (programmed cell-death) processes 
(Johnstone et al 2002; Reed 2006). Several molecules that 
block cell death have been identiﬁ  ed, and some have been 
targeted for pharmacologic intervention. One such group of 
molecules is the Bcl-2 family, which includes 6 antiapoptotic 
proteins (Reed 2006). Overexpression of one or more of 
these antiapoptotic proteins, the most recognized of which 
is Bcl-2, essentially acts as a survival factor for cancer cells 
and is associated with resistance to chemotherapy in a number 
of hematologic cancers and solid tumors (Reed et al 1994; 
Klasa et al 2002; Reed 2006).
The BCL2 gene was originally described in association 
with the t(14;18) chromosomal abnormality identiﬁ  ed in 
B-cell lymphoma, and the resultant Bcl-2 protein was found 
to inhibit cell death (Tsujimoto and Shimizu 2000). Data 
suggest that Bcl-2 negatively regulates the size or voltage 
potential of a mitochondrial-transmembrane pore by interact-
ing with the pro-apoptotic protein Bax (Cheng et al 2001; 
Tsujimoto and Shimizu 2002). A Bcl-2/Bax-regulated pore is 
functionally similar to a switch that is either open or closed. 
In the open conﬁ  guration, cytochrome C and calcium are 
released into the cytoplasm, thus initiating caspase activation 
and irreversibly committing the cell to death (Basañez et al 
1999; Wang 2001; Kokoszka et al 2004; Sharpe et al 2004). 
By closing the pores through which cytochrome C is released, 
Bcl-2 negatively regulates apoptosis. Thus, the Bcl-2 protein 
is a fundamental contributor to both inherent and acquired 
resistance of cancer cells to chemotherapy (Johnstone et al 
2002).
Expression of the Bcl-2 protein has been documented in 
virtually all patients with CLL (Schena et al 1992; Hanada et 
al 1993; Robertson et al 1996; Zaja et al 1998; Aviram et al 
2000; Cheng et al 2001; Wang 2001; Klobusicka et al 2002; 
Menendez et al 2004; Tracey et al 2005). It is widely rec-
ognized that Bcl-2 upregulation plays a critical role in CLL 
and is associated with the pathogenesis of this malignancy 
(Schena et al 1992; Hanada et al 1993; Robertson et al 1996; 
Faderl et al 2002). The most frequent chromosomal deletion 
identiﬁ  ed by ﬂ  uorescence in situ hybridization in patients 
with CLL occurs in chromosome 13q14 (Döhner et al 2000). 
13q14 deletions eliminate micro RNA (miRNA) regulators 
of Bcl-2 expression, resulting in enhanced Bcl-2 expression. 
Notably, re-introduction of miRNAs in a lymphoid cell line 
was observed to downregulate Bcl-2 and induce apoptosis 
(Cimmino et al 2005; Calin and Croce 2006).
Antisense DNA oligonucleotides that bind RNA can 
target speciﬁ  c proteins, induce enzymatic cleavage of the 
message, and thereby prevent protein translation (Curcio et al 
1997). Oblimersen (Genasense®, Bcl-2 antisense, G3139) 
is a synthetic, 18-base, single-stranded phosphorothio-
ate DNA oligonucleotide designed to downregulate bcl-2 
mRNA expression (Klasa et al 2002). Oblimersen selectively 
hybridizes to the ﬁ  rst 6 codons of the open reading frame that 
encodes the Bcl-2 protein. Formation of the RNA/antisense 
DNA duplex recruits RNase H, which degrades the RNA 
strand and releases the antisense DNA strand, allowing the 
drug to bind and cleave additional bcl-2 RNA molecules, 
thus preventing translation of the Bcl-2 protein.
Multiple nonclinical models demonstrate the effects 
of oblimersen, including reduced Bcl-2 levels, reduced 
cell viability, increased activity of apoptotic mechanisms, 
reduction in tumor size, and enhanced activity of cytotoxic 
anticancer drugs (Klasa et al 2002). These ﬁ  ndings have 
been documented following exposure to oblimersen alone 
and to oblimersen in combination with other therapeutic 
agents or modalities, including chemotherapy and radio-
therapy, in tumor types that include B-cell neoplasias, 
myeloid leukemia, and many solid tumors (Gazitt et al 
2001; Klasa et al 2002). A summary of ﬁ  ndings in several 
nonclinical models of hematologic malignancies, including Therapeutics and Clinical Risk Management 2007:3(5) 857
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CLL, is provided in Table 1. Overall, given the prevalence of 
Bcl-2 overexpression in diverse cancers, nonclinical ﬁ  ndings 
suggest that oblimersen may function in tumors from a broad 
range of genetic backgrounds. This observation underscores 
the importance of apoptosis as the mechanism of cell death 
induced by many anticancer therapies (Reed 2006).
Clinical pharmacology
Pharmacokinetics
The pharmacokinetics of oblimersen have previously been 
reported (Demidov et al 2003; O’Brien et al 2005; Tolcher 
et al 2005; Rheingold et al 2007) and are consistent with those 
reported for other phosphorothioate oligonucleotides.
Oblimersen is rapidly metabolized, primarily by 
exonuclease-mediated cleavage that sequentially removes 
single nucleotides from the parent oligonucleotide, yielding a 
mononucleotide metabolite and the parent molecule shortened 
by 1 nucleotide (eg, N-1 [a 17-mer] and N-2 [a 16-mer]) (data 
on ﬁ  le, Genta Incorporated). The primary metabolites (N-1 
and N-2) have been measured in pharmacokinetic studies and 
have been shown to be biologically active. In some published 
studies, pharmacokinetic parameters reported for oblimersen 
were based on the sum of oblimersen and its metabolites 
because the analytical methods used did not resolve the parent 
molecule from the chain-shortened metabolites.
Steady-state plasma concentrations of oblimersen and 
the N-1 and N-2 metabolites are rapidly achieved (within 
6–10 hours) after initiation of Genasense administration 
by continuous intravenous infusion (data on ﬁ  le, Genta 
Incorporated). Exposure (based upon Css) to the N-1 and N-
2 metabolites is approximately 38%–50% and 13%–42%, 
respectively, of the exposure to oblimersen over a dose range 
of 3–7 mg/kg/d (Demidov et al 2003; O’Brien et al 2005). At 
doses ranging from 3 to 7 mg/kg/d, steady-state plasma con-
centrations and oblimersen exposure increase with increasing 
doses, appear consistent with linear pharmacokinetics, and 
are not dependent on gender or age (Sekar et al 2005).
Oblimersen is rapidly cleared from the plasma after 
its administration (t1/2 ∼ 2.4 hours) (O’Brien et al 2005; 
data on ﬁ  le, Genta Incorporated). Renal clearance of intact 
oblimersen represents only a small portion of the total clear-
ance (O’Brien et al 2005; data on ﬁ  le, Genta Incorporated), 
as reported for other phosphorothioate oligonucleotides 
(Cossum et al 1993, 1994; Crooke et al 1994). Its rapid clear-
ance from the plasma is consistent with data published on 
other phosphorothioate oligonucleotides and reﬂ  ects rapid 
and wide distribution into tissues, as demonstrated preclini-
cally (Raynaud et al 1997).
The pharmacokinetics of oblimersen are currently being 
studied in patients with hepatic impairment and patients 
with renal impairment. Preliminary data from 1 patient with 
moderately impaired hepatic function (ie, Child-Pugh Clas-
siﬁ  cation B) enrolled to date indicated no change in oblim-
ersen clearance or metabolism, compared with ﬁ  ndings in 
2 patients with normal hepatic function (data on ﬁ  le, Genta 
Incorporated). Preliminary data from the study in patients 
with renal impairment are not yet available.
In an ongoing study of oblimersen administration by sub-
cutaneous injection, administration of 225 mg to patients with 
solid tumors resulted in peak plasma levels of approximately 
3 µg/mL, similar to steady-state levels achieved with admin-
istration of oblimersen 7 mg/kg/d by continuous intravenous 
infusion (data on ﬁ  le, Genta Incorporated).
Pharmacodynamics
Uptake of oblimersen into patient cells and downregulation 
of bcl-2 mRNA with a decrease in Bcl-2 protein has been 
demonstrated in clinical studies. Marcucci et al assessed the 
pharmacodynamics of oblimersen in patients with relapsed 
or refractory acute myeloid leukemia (Marcucci et al 2003). 
Patients received oblimersen as a 10-day continuous infusion, 
ﬂ  udarabine and cytarabine starting on Day 6, and G-CSF 
starting on Day 5. Bone marrow aspirates from 12 patients 
were assessed for bcl-2 mRNA, of which 9 (75%) showed 
downregulation. Retained samples of bone marrow and 
peripheral blood mononuclear cells from 8 patients were 
subsequently assayed for intracellular oblimersen drug levels 
(Dai et al 2005). Signiﬁ  cant cellular uptake of oblimersen was 
observed in mononuclear cells from both bone marrow and 
blood. Among the 8 patients, downregulation of bcl-2 mRNA 
in bone marrow was observed in 4 patients; bcl-2 mRNA was 
unchanged in 2 patients and increased in 2 patients.
These same investigators assessed the relationship 
between clinical response, plasma and intracellular oblim-
ersen levels, and changes in bcl-2 mRNA and Bcl-2 protein 
levels in bone marrow mononuclear cells in 22 elderly 
patients treated with oblimersen and chemotherapy for 
previously untreated acute myeloid leukemia (Marcucci 
et al 2005). Patients who achieved a complete response 
showed decreases in median bcl-2 mRNA and protein levels 
relative to baseline. In contrast, nonresponding patients 
showed upregulation of bcl-2 mRNA and no change in 
Bcl-2 protein levels.
Reduction of Bcl-2 protein levels in peripheral blood 
mononuclear cells was observed in pediatric patients with solid 
tumors after administration of oblimersen at doses of 3, 5, and Therapeutics and Clinical Risk Management 2007:3(5) 858
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7 mg/kg/d (Rheingold et al 2007). Bcl-2 protein levels were 
reduced by Day 5 in 9 of 15 patients, including 6 of 9 patients 
treated with oblimersen 3 mg/kg/d, as shown in Figure 1.
Clinical studies
Oblimersen is undergoing clinical evaluation in a number of 
hematologic malignancies (eg, acute myeloid leukemia, CLL, 
multiple myeloma, and various lymphomas) and solid tumors 
(eg, advanced melanoma, breast cancer, gastrointestinal stro-
mal tumors, nonsmall cell lung cancer, and prostate cancer). 
To date, 3 studies have been conducted with oblimersen in 
CLL (see Table 2), including administration as a single agent 
in a Phase I-II study (O’Brien et al 2005), in combination with 
ﬂ  udarabine and rituximab in a Phase II study (Mavromatis 
et al 2005, 2006), and in combination with ﬂ  udarabine and 
cyclophosphamide in a Phase III study (Rai et al 2005; 
O’Brien et al 2007). A total of 179 patients enrolled across the 
3 studies have received oblimersen alone or in combination 
with chemotherapy. In each of the 3 studies, response was 
Figure 1 Bcl-2 response in peripheral blood mononuclear cells from pediatric 
patients with solid tumors by oblimersen dose: change from baseline (Day 0) on 
Day 5 (No Day 5 sample for 2 patients; response on Day 6 shown. Copyright © 
2007. Reprinted with permission from the American Society of Clinical Oncology 
from Rheingold SR, Hogarty MD, Blaney SM, et al. 2007. A Phase I trial of G3139, a 
bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide 
in children with relapsed solid tumors: A Children’s Oncology Group study. J Clin 
Oncol, 25:1512–18.
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Cheson
assessed according to the National Cancer Institute Working 
Group (NCI-WG) Guidelines (Cheson et al 1996).
Phase I-II studies
In the Phase I-II study, 40 patients with relapsed or refractory 
CLL were treated with single-agent oblimersen at doses of 
3 to 7 mg/kg/d (see Table 2), including 14 patients in Phase 
I and 26 patients in Phase II (O’Brien et al 2005). All but 9 
patients received at least 2 cycles of treatment; the 9 patients 
included 7 who discontinued due to an adverse event, 3 of 
whom had received oblimersen in Phase I at a dose of 4, 5, 
or 7 mg/kg/d (data on ﬁ  le, Genta Incorporated). The maxi-
mum tolerated dose determined in Phase I was 3 mg/kg/d: 
the oblimersen dose was limited by the occurrence of an 
infusion reaction with or without tumor lysis at doses greater 
than 3 mg/kg/d. This reaction typically occurred in the ﬁ  rst 
24 to 48 hours of oblimersen administration and included 
high spiking fevers, rigors, and hypotension. The reaction is 
attributed to extensive apoptosis of B-lymphocytes and the 
resultant release of large quantities of cytokines directly into 
the systemic circulation. It has not been observed in patients 
with solid tumors, who are typically treated with oblimersen 
doses greater than 3 mg/kg/d and in whom cell destruction 
occurs more slowly than in patients with circulating tumor-
cell populations.
A partial response was documented in 2 of 26 (8%) evalu-
able patients (1 in Phase I and 1 in Phase II) after 2 cycles 
(O’Brien et al 2005). It is noteworthy that both patients had 
been previously treated with at least 4 prior chemotherapy 
regimens (O’Brien et al 2005), and one had a history of 
Richter’s transformation prior to entering the study (data on 
ﬁ  le, Genta Incorporated). One of the 2 patients had disease 
progression by Cycle 6 and 1, disease progression by Cycle 7. 
Of the remaining 24 patients, 13 had stable disease for at 
least 2 months and 11 had progressive disease by the end of 
the second cycle (O’Brien et al 2005).
Evidence of single-agent oblimersen activity also included 
a  50% reduction from baseline in splenomegaly in 7/17 
Table 2 Overview of clinical studies conducted in CLL
Design  Oblimersen regimen and accompanying chemotherapy, if 
  applicable
  Length of cycle; maximum number of cycles 
Relapsed or refractory   Phase I: Oblimersen 3, 4, 5, and 7 mg/kg/d by continuous intravenous 
patients: Phase I/II   infusion for 5 days in Cycle 1 and for 7 days in cycles subsequent to 
multicenter study with dose   Cycle 1 
ﬁ  nding/dose escalation in   Phase II: Oblimersen 3 mg/kg/d by continuous intravenous infusion for 
Phase I (O’Brien et al 2005)   5 days in Cycle 1 and for 7 days in cycles subsequent to Cycle 1 
  21-day cycle; maximum of 12 cycles for responding patients; maximum 
  of 6 cycles for all other patients
Previously treated and   Part I: Cycle 1, oblimersen 1.5 mg/kg/d by continuous intravenous 
untreated patients: Phase II,   infusion for 7 days; rituximab 125 mg/m2 by intravenous infusion on 
multicenter (Mavromatis et al   Day 4 and 250 mg/m2 by intravenous infusion on Day 6; ﬂ  udarabine 
2005, 2006)   25 mg/m2 by intravenous infusion on Days 6 through 8; Cycles 2–6, 
  oblimersen 3 mg/kg/d by continuous intravenous infusion for 7 days; 
  rituximab 375 mg/m2 by intravenous infusion on Day 5 followed by 
  ﬂ  udarabine 25 mg/m2 by intravenous infusion on Day 5; ﬂ  udarabine 
  25 mg/m2 by intravenous infusion on Days 6 and 7 
  Part II: All cycles, oblimersen 3 mg/kg/d by continuous intravenous 
  infusion for 7 days; rituximab 375 mg/m2 by intravenous infusion on 
  Day 5 followed by ﬂ  udarabine 25 mg/m2 by intravenous infusion on 
  Day 5; ﬂ  udarabine 25 mg/m2 by intravenous infusion on Days 6, 7, 8, 
  and 9 
  28-day cycle; for previously untreated patients, maximum of 6 cycles; 
  for previously treated patients, maximum of 4 cycles with additional 2 
  cycles permitted at investigator’s discretion 
Relapsed or refractory   Oblimersen 3 mg/kg/d by continuous intravenous infusion for 7 days 
patients: Phase III   and ﬂ  udarabine 25 mg/m2/d by intravenous infusion followed by 
multinational, multicenter,   cyclophosphamide 250 mg/m2/d by intravenous infusion on Days 5, 6, 
randomized, controlled, open-  and 7 
label study (Rai et al 2005;   28-day cycle for up to 6 cycles 
O’Brien et al 2007) 
Abbreviation: Flu/Cy, ﬂ  udarabine/cyclophosphamide.Therapeutics and Clinical Risk Management 2007:3(5) 861
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patients (41%), a  50% reduction from baseline in lymph 
node size in 7/22 patients (32%), and a  50% reduction 
from baseline in absolute lymphocyte count in 11/22 patients 
(50%) who had an absolute lymphocyte count >5,000/µL at 
baseline (O’Brien et al 2005).
The adverse event proﬁ  le of oblimersen in patients with 
CLL was well deﬁ  ned in this study. Most events were Grade 1 
or Grade 2 (ie, mild or moderate) in severity (National Cancer 
Institute Common Toxicity Criteria [NCI-CTC], Version 2.0) 
(data on ﬁ  le, Genta Incorporated). The most common events 
were pyrexia (33% of patients); fatigue (30%); cough and 
hypotension (20% each); and anemia, thrombocytopenia, 
nausea, and night sweats (18% each) (O’Brien et al 2005; 
data on ﬁ  le, Genta Incorporated). The single dose-limiting 
toxicity was an infusion reaction with or without tumor lysis, 
which occurred at doses greater than 3 mg/kg/d. No patient 
died due to an adverse event related to oblimersen (data on 
ﬁ  le, Genta Incorporated).
Catheter-related complications occurred in 6 (15%) 
patients and included erythema, bruising, bleeding, pain, 
cellulitis, and phlebitis at the intravenous administration 
site (data on ﬁ  le, Genta Incorporated). All but one of these 
events were Grade 1 or Grade 2 in severity (NCI-CTC); the 
one exception was a severe occurrence of phlebitis. None of 
these events result in discontinuation of study treatment.
In the Phase II trial, 24 patients, including 5 who had 
not previously been treated and 19 who had been previ-
ously treated, received oblimersen in combination with 
rituximab and ﬂ  udarabine (see Table 2) (Mavromatis et al 
2005, 2006). Oblimersen treatment was initiated at a dose 
of 1.5 mg/kg/d in Cycle 1 and adjusted to 3 mg/kg/d in 
subsequent cycles. The median number of cycles admin-
istered was 6.
Responses (complete, nodular partial, or partial) were 
observed in all 5 (100%) previously untreated patients and 
13 (68%) of 19 previously treated patients (see Figure 2) 
(Mavromatis et al 2006). A complete response was achieved 
in 1 previously untreated patient and 1 previously treated 
patient; both patients had a negative ﬂ  ow-cytometric response 
and a negative polyclonal response for IgH gene rearrange-
ment.
Baseline characteristics among the responding patients 
included elevated CD38 expression in CLL cells in 3 of the 
5 previously untreated patients and 6 of the 13 previously 
treated patients (Mavromatis et al 2006). Also among the 
13 previously treated patients who responded, 5 patients 
had elevated Zap-70 (including 1 patient with a molecular 
CR [deﬁ  ned as absence of IgH gene rearrangement based 
on ﬂ  ow cytometry and polymerase chain reaction analysis]), 
2 patients had poor-risk cytogenetics (11q deletion) at 
Figure 2 Overall response in previously untreated and previously treated patients with CLL: Phase II study.
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baseline, and 9 patients were “sensitive” to the previously 
administered therapy (ie, they had achieved a response to 
prior therapy that had lasted for at least 6 months). These prior 
therapies included ﬂ  udarabine and rituximab administered 
alone or in combination with other agents.
Adverse events tended to be Grade 1 or Grade 2 in 
severity (NCI-CTC) (data on ﬁ  le, Genta Incorporated). 
The most frequently reported complications among the 24 
treated patients included rigors (58% of patients); neutrope-
nia (54%); nausea (50%); fatigue and pyrexia (46% each); 
drug hypersensitivity (32%); thrombocytopenia (33%); 
anemia (29%); diarrhea, insomnia, and rash (25% each); 
and headache (21%). Many of these events were consistent 
with those reported in the Phase I-II study of single-agent 
oblimersen; the exceptions (eg, drug hypersensitivity, rash, 
diarrhea, insomnia) are events reported with one or both of 
the coadministered chemotherapy agents (ﬂ  udarabine or 
rituximab). The drug hypersensitivity reactions were clearly 
associated with rituximab administration. No patient had an 
adverse event with an outcome of death (data on ﬁ  le, Genta 
Incorporated).
Catheter-related complications occurred in 5 (24%) 
patients (data on ﬁ  le, Genta Incorporated). These included 
swelling of the extremity secondary to the intravenous 
infusion, pain or soreness at the administration site, loss of 
line patency, and line occlusion. All of these events were 
Grade 1 or Grade 2 in severity (NCI-CTC), and none resulted 
in discontinuation of study treatment.
Of interest was the absence of tumor lysis syndrome and 
infusion reactions in the ﬁ  rst treatment cycle, during which 
oblimersen was administered at the reduced dose of 1.5 
mg/kg/d. The only infusion reaction occurred in Cycle 3 and 
was conﬁ  rmed to be associated with rituximab administration 
(data on ﬁ  le, Genta Incorporated). The patient continued in 
the study, receiving oblimersen and ﬂ  udarabine in the remain-
ing 3 cycles without recurrence of this event.
Phase III study
In the Phase III study, 241 patients with relapsed or refrac-
tory CLL were stratiﬁ  ed according to 3 criteria: responsive 
versus refractory to prior ﬂ  udarabine therapy, number of 
prior regimens (1 or 2 versus  3), and duration of response 
to last prior therapy ( 6 months versus  6 months) (Rai 
et al 2005; O’Brien et al 2007). Patients were centrally 
randomized to treatment with oblimersen, ﬂ  udarabine, and 
cyclophosphamide (oblimersen plus Flu/Cy group, N = 120) 
or the ﬂ  udarabine-cyclophosphamide regimen alone (Flu/Cy 
group, N =121; see Table 2).
Primary eligibility criteria included measurable and 
active disease (NCI-WG Guidelines; Cheson et al 1996); 
intermediate- or high-risk stage (modified Rai criteria; 
Cheson et al 1996); history of relapse from or no response to 
 1 prior chemotherapy regimen, at least one of which must 
have included 2 or more cycles of ﬂ  udarabine; and ECOG 
performance status  2.
Response and disease progression were centrally deter-
mined (O’Brien et al 2007). Bone marrow specimens were 
assessed by an independent hematopathologist blinded to study 
treatment and clinical information, and clinical response and 
progression were determined by a CLL expert (Dr Kanti Rai) 
blinded to study treatment. For patients followed by CT/ultra-
sound from baseline (which is allowed but not required by 
NCI-WG Guidelines; Cheson et al 1996), these radiographic 
studies were required to have normalized before bone marrow 
biopsy was performed to conﬁ  rm response.
The primary efficacy endpoint was response rate 
(complete response plus nodular partial response) in the 
intent-to-treat population, as determined by the blinded CLL 
expert. In determining sample size, it was assumed that the 
response rate would be 24% for the chemotherapy-only 
group versus 44% for the oblimersen plus Flu/Cy group. A 
minimum of 200 patients (100 per treatment arm) was needed 
to provide a power of 80% at an overall alpha of 0.05 (two-
sided), accounting for the protocol-speciﬁ  ed interim analysis 
using a Chi square test.
The 2 groups generally were well balanced at baseline 
(see Table 3) (O’Brien et al 2007). There was an approximate 
1-year difference between treatment groups in the median 
time from initial diagnosis to randomization, with patients 
in the oblimersen plus Flu/Cy group having had CLL for a 
longer period than those in the Flu/Cy group. Approximately 
75% of patients in both groups had abnormal radiographic 
ﬁ  ndings at baseline.
In both groups, 115 patients received protocol therapy, 
and the median number of cycles administered was 4 (O’Brien 
et al 2007). In addition, ﬂ  udarabine and cyclophosphamide 
were administered at or close to the doses speciﬁ  ed by pro-
tocol in both treatment groups. Across all cycles, the actual 
dose of ﬂ  udarabine administered compared with the planned 
dose averaged 91% in the oblimersen plus Flu/Cy group and 
93% in the Flu/Cy group; corresponding percentages for 
cyclophosphamide were 90 and 93, respectively (data on 
ﬁ  le, Genta Incorporated). The most common reason for early 
discontinuation was adverse event/toxicity (36% and 35% 
of patients in the oblimersen plus Flu/Cy group and Flu/Cy 
group, respectively).Therapeutics and Clinical Risk Management 2007:3(5) 863
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The primary endpoint of the study was achieved: the 
addition of oblimersen to the standard chemotherapy sig-
niﬁ  cantly increased the rate of complete plus nodular partial 
responses. Twenty (17%) of 120 patients in the oblimersen 
plus Flu/Cy group achieved a complete or nodular par-
tial response versus 8 (7%) of 121 patients in the Flu/Cy 
group (P = 0.025; see Table 4) (Rai et al 2005; O’Brien et 
al 2007). Importantly, the rate of complete response was 
more than tripled in the oblimersen plus Flu/Cy group 
(11 [9%] patients versus 3 [2%] patients in the Flu/Cy 
group [P = 0.03]) (O’Brien et al 2007). Consistent with the 
observation in the Phase II study (Mavromatis et al 2006), 
patients who remained sensitive to ﬂ  udarabine were those 
most apt to respond to the addition of oblimersen to standard 
chemotherapy (see Table 4). This ﬁ  nding was not apparent 
among responding patients treated with Flu/Cy alone. Also 
consistent with the Phase II study, responses were achieved 
in patients with cytogenetic factors associated with an adverse 
prognosis (oblimersen plus Flu/Cy group, 2 patients with 17p 
or 11q deletions among the 9 of 20 responding patients with 
cytogenetic data at baseline) (O’Brien et al 2007).
All complete and nodular responses were durable, lasting 
6 or more months (see Figure 3) (O’Brien et al 2007). Follow-
up through a minimum of 2 years showed a relapse rate of 
25% (5 of 20 patients in the oblimersen plus Flu/Cy group) 
versus 75% (6 of 8 patients) in the Flu/Cy group. Median 
duration of CR/nPR was 20 months in the Flu/Cy group and 
not reached in the oblimersen plus Flu/Cy group, in which it 
is estimated that duration will exceed 31 months. Moreover, 
based on an intent-to-treat analysis of response duration, a 
highly signiﬁ  cant difference was apparent that favored the 
oblimersen plus Flu/Cy group (hazard ratio = 0.62; P = 0.002; 
see Figure 4.
Time to progression was correlated with response 
(P   0.0001) (O’Brien et al 2007). Among patients with 
a complete or nodular partial response, 70% of patients 
(14 of 20) in the oblimersen plus Flu/Cy group versus 50% 
(4 of 8) in the Flu/Cy group were without disease progression 
Table 4 Complete and partial nodular responses by prior 
treatment history and treatment group: Phase III study, intent-to-
treat population
  Oblimersen plus   Flu/Cy
 Flu/Cy  (N  =  121)
  (N = 120)  n/N (%)
 n/N  (%) 
Response  
  Complete or nodular  
  partial response  20/120 (17)a 8/121  (7)a 
  Complete response  11/120 (9)b   3/121 (3)b
Fludarabine sensitivity   
  Relapsed  13/51 (25)  3/50 (6)
  Refractory  7/69 (10)  5/71 (7)
Number of prior regimens   
  1–2  14/60 (23)  4/63 (6)
  3 or more  6/60 (10)   4/58 (7)
Response to last therapy   
   6 months  12/54 (22)   3/52 (6) 
   6 months  8/66 (12)  5/69 (7) 
Abbreviation: Flu/Cy, ﬂ  udarabine/cyclophosphamide.
aP, 0.025, continuity-corrected Chi square test
bP, 0.03, Fisher’s exact test
Copyright © 2007. Reprinted with permission from the American Society of 
Clinical Oncology from O’Brien S, Moore JO, Boyd TE, et al. Randomized Phase 
3 trial of ﬂ  udarabine plus cyclophosphamide with or without oblimersen sodium 
(Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic 
leukemia. J Clin Oncol, 25:1114–20.
Table 3 Demographic and disease characteristics at baseline by 
treatment group: Phase III study, intent-to-treat population
Characteristic Oblimersen  plus
 Flu/Cy  Flu/Cy
  (N = 120)  (N = 121)
Mean age, years  62.5  62.0
  Median (minimum, maximum)  62.5 (35, 86)  63.0 (42, 82)
Age group, n (%)   
   65 years  67 (56)  69 (57)
   65 years  53 (44)  52 (43)
   75 years  17 (14)  10 (8)
Gender, n (%)   
  Male  89 (74)  89 (74)
 Female  31  (26)  32  (26)
Race, n (%)   
  White, not of Hispanic origin  105 (88)  109 (90)
  Black, not of Hispanic origin  6 (5)  7 (6)
  Hispanic   8 (7)  4 (3)
  Other  1 (1)  1 (1)
Time from initial diagnosis to   
randomization, months   
  Median (minimum, maximum)  70.2 (2.4, 383.8)  58.1 (2.2, 249.6)
Modiﬁ  ed Rai Stage, n (%)   
  0–I  29 (24)  29 (24)
  II–IV  91 (76)  91 (75)
  Unknown  0 (0)  1 (1)
Lymphocyte immunophenotype, 
n (%)   
  CD5  120 (100)  121 (100)
  CD19  120 (100)  119 (98)
  CD20  101 (84)  97 (80)
Number of prior regimens, n (%)   
  1 or 2  60 (50)  63 (52)
   3  60 (50)  58 (48)
Abbreviation: Flu/Cy, ﬂ  udarabine/cyclophosphamide. (Copyright © 2007. 
Reprinted with permission from the American Society of Clinical Oncology from 
O’Brien S, Moore JO, Boyd TE, et al. Randomized Phase 3 trial of ﬂ  udarabine plus 
cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients 
with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol, 25:1114–20. 
data on ﬁ  le, Genta Incorporated).Therapeutics and Clinical Risk Management 2007:3(5) 864
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Figure 3 Duration of response (from date of ﬁ  rst response) during and following protocol therapy among patients achieving a CR or nPR by treatment group: Phase III Study 
(Copyright © 2007. Reprinted with permission from the American Society of Clinical Oncology from O’Brien S, Moore JO, Boyd TE, et al. Randomized Phase 3 trial of ﬂ  udara-
bine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol, 25:1114–20).
Figure 4 Duration of response from date of best response by treatment group: Phase III study, intent-to-treat population (data on ﬁ  le, Genta Incorporated).
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2 or more years after randomization. Similarly, survival was 
correlated with response (P   0.0001; see Figure 5) (O’Brien 
et al 2007). Among patients with a complete or nodular par-
tial response, 70% of patients in the oblimersen plus Flu/Cy 
group versus 38% in the Flu/Cy group were alive 3 years 
after randomization. Based on an intent-to-treat analysis, 
the estimated 3-year survival rate was 46% and 37% in the 
oblimersen plus Flu/Cy and Flu/Cy groups, respectively.
Additional clinical beneﬁ  t afforded with the achievement 
of a complete or nodular partial response was the disap-
pearance of CLL symptoms for  180 days (P   0.0001 for 
CR/nPR versus PR versus   PR) (O’Brien et al 2007). As 
speciﬁ  ed by protocol, these symptoms included fever, night 
sweats, fatigue, abdominal discomfort or early satiety due to 
hepatosplenomegaly, impaired cosmesis or impaired mobil-
ity due to lymphadenopathy, and “other.” Among patients 
who were symptomatic at baseline regardless of treatment 
group, 17 (94%) of patients with a complete or nodular 
partial response versus 36 (59%) with a partial response 
were symptom-free for at least 180 days prior to disease 
progression or initiation of new therapy. Patients with a 
complete or nodular partial response were afforded a mini-
mum of approximately 11 additional symptom-free months 
compared with patients who had a partial response.
The oblimersen plus Flu/Cy regimen was superior across 
all prospectively deﬁ  ned strata. Analysis showed that certain 
patients disproportionately benefited from the addition 
of oblimersen to standard chemotherapy (Rai et al 2005; 
O’Brien et al 2007). In particular, ﬂ  udarabine-responsive 
patients, ie, those who had achieved a partial response or 
better for at least 6 months after ﬂ  udarabine therapy and 
then relapsed (oblimersen plus Flu/Cy group, N = 51; Flu/Cy 
group, N = 50), derived maximal beneﬁ  t from the addition of 
oblimersen to ﬂ  udarabine and cyclophosphamide (O’Brien 
et al 2007). The beneﬁ  cial effect of oblimersen in the ﬂ  uda-
rabine-responsive population was apparent both for CR and 
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nPR (oblimersen plus Flu/Cy group, 25%; Flu/Cy group, 
6%; P = 0.016).
Importantly, in this group of ﬂ  udarabine-responsive 
patients, there was a statistically signiﬁ  cant beneﬁ  t in survival 
for the oblimersen plus Flu/Cy group (O’Brien et al 2007). 
The median overall survival with 3 years of follow-up for all 
patients was not reached in the oblimersen plus Flu/Cy group 
and was 33 months in the Flu/Cy group (hazard ratio = 0.53; 
P = 0.05; see Figure 6).
This randomized, controlled study allowed identiﬁ  ca-
tion of those adverse events that may be exacerbated when 
oblimersen is added to standard chemotherapy. The most 
frequently reported adverse events (all grades) among the 
115 patients treated with oblimersen plus Flu/Cy included 
nausea (72% of patients), thrombocytopenia (49%), pyrexia 
(48%), fatigue (44%), anemia (39%), and vomiting (30%) 
(see Table 5) (O’Brien et al 2007; data on ﬁ  le, Genta Incor-
ported). Except for anemia and neutropenia, more patients 
treated with oblimersen plus Flu/Cy than Flu/Cy alone 
experienced these frequently reported events.
With the exception of thrombocytopenia and neutropenia, 
most adverse events were Grade 1 or Grade 2 in severity 
(NCI-CTC) (data on ﬁ  le Genta Incorporated). Consistent with 
an increased incidence of Grade 3 or Grade 4 thrombocytope-
nia in the oblimersen plus Flu/Cy group (see Table 5), platelet 
transfusions were administered to more patients in the oblim-
ersen plus Flu/Cy group than in the Flu/Cy group. For the 
most part, these transfusions were administered primarily in 
Cycle 1 to patients with baseline platelet counts of  10,000 
but  25,000 (see Table 6) (data on ﬁ  le, Genta Incorporated). 
Importantly, as shown in Table 6, most transfusions were not 
associated with a bleeding event, and the incidence of Grade 
3–4 bleeding events was low in both groups (4% and 2%, 
respectively). Given that the Flu/Cy standard of care is highly 
immunosuppressive and myelosuppressive, it is noteworthy 
that the addition of Genasense to the Flu/Cy regimen did not 
increase the incidence of neutropenia or anemia (all grades, 
as well as Grade 3–4 occurrences).
Catheter-related complications, all of which were 
Grade 1 or 2 in severity, were reported for 16% and 3% of 
patients in the oblimersen plus Flu/Cy and Flu/Cy groups, 
respectively (O’Brien et al 2007). These events mainly 
consisted of tenderness, bruising, redness, swelling, and 
seepage at the catheter site. None of these events resulted 
           No. of months
Figure 6 Kaplan-meier survival curves by treatment group: Phase III study, intent-to-treat population, ﬂ  udarabine-responsive patients (Copyright © 2007. Reprinted with 
permission from the American Society of Clinical Oncology from O’Brien S, Moore JO, Boyd TE, et al. Randomized Phase 3 trial of ﬂ  udarabine plus cyclophosphamide with 
or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol, 25:1114–20).Therapeutics and Clinical Risk Management 2007:3(5) 867
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in discontinuation of study treatment (data on ﬁ  le, Genta 
Incorporated).
Of particular concern in patients with CLL is the occur-
rence of opportunistic infections and second malignancies, 
neither of which was increased with the addition of oblim-
ersen to chemotherapy (opportunistic infections: oblimersen 
plus Flu/Cy group, 4%; chemotherapy-only group, 7%; 
second malignancies: 1% and 4%, respectively) (O’Brien 
et al 2007). Also noteworthy in the ﬁ  rst cycle of therapy in 
the oblimersen plus Flu/Cy group is the low incidence of 
infusion-related events, which were limited to tumor lysis 
syndrome in two (2%) patients and a cytokine-release-type 
reaction in one (1%) patient.
Treatment-related adverse events with an outcome of 
death were uncommon in both groups (oblimersen plus 
Flu/Cy group, 5 [4%]; Flu/Cy group, 2 [2%]). Causes of 
death in the two treatment groups were fairly similar except 
for two deaths due to tumor lysis/cytokine release syndrome 
in the oblimersen plus Flu/Cy group.
In the ﬂ  udarabine-responsive treated population (oblim-
ersen plus Flu/Cy group, N = 47; chemotherapy-only group, 
N = 49), adverse events were quantitatively and qualitatively 
similar to those reported for all treated patients in the Phase 
III study (see Table 7) (data on ﬁ  le, Genta Incorporated). 
Only 3 events of Grade 3–4 severity occurred in more 
than 10% of patients in either group – thrombocytopenia, 
Table 5 Frequently reported adverse events by treatment group: Phase III study, all treated patients 
  All    Grade 3 + Grade 4
  Oblimersen     Oblimersen  
  plus Flu/Cy  Flu/Cy  plus Flu/Cy  Flu/Cy
  (N = 115)  (N = 115)  (N = 115)  (N = 115)
Adverse event a %  %  %  %
Nausea 72 48  8  2
Thrombocytopenia 49  40  33  20
Pyrexia 49 29  3 3
Fatigue 44 31  6 4
Anemia 39 42  15 15
Vomiting 30  23  6  1
Cough 28 22  1 0
Constipation 26  19  2  1
Neutropenia 24  33  19  24
Headache 23  14  1  3
Diarrhea 22  14  1  1
Dyspnea 21  17  5  2
Abbreviation: Flu/Cy, ﬂ  udarabine/cyclophosphamide.
aIncludes events reported in  20% of patients in either treatment group
(Copyright © 2007. Reprinted with permission from the American Society of Clinical Oncology from O’Brien S, Moore JO, Boyd TE, et al. Randomized Phase 3 trial of 
ﬂ  udarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol, 
25:1114–20.; data on ﬁ  le, Genta Incorporated).
Table 6 Platelet count at baseline and at time of ﬁ  rst transfusion by treatment group: Phase III study, all treated patients
   100,000 at baseline     100,000 at baseline
  Oblimersen plus     Oblimersen plus  
 Flu/Cy  Flu/Cy  Flu/Cy  Flu/Cy
  (n = 41)  (n = 39)  (n = 74)  (n = 76)
  No. of patients  No. of patients  No. of patients  No. of patients
Patients with platelet count at   9  2  6  2
time of ﬁ  rst transfusiona      
Platelet count  10,000 2  1b 1  0
Platelet count  10,000 –  25,000 7c 1  5d 2 e
Abbreviations: Flu/Cy, ﬂ  udarabine/cyclophosphamide; no., number.
aThe lower of either the last platelet count prior to transfusion or the ﬁ  rst platelet count after transfusion
bThis patient had rectal bleeding (Grade 1).
cOne patient had hematuria (Grade 2).
dOne patient had a subepidermal hemorrhage (Grade 3).
eOne patient had a hemorrhagic disorder (Grade 3).
(data on ﬁ  le, Genta Incorporated)Therapeutics and Clinical Risk Management 2007:3(5) 868
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neutropenia, and anemia. The incidence of both neutropenia 
and anemia was signiﬁ  cantly increased in the Flu/Cy group 
compared with the oblimersen plus Flu/Cy group (P = 0.03). 
No infusion-related reactions occurred in either group in the 
ﬂ  udarabine-responsive population. The beneﬁ  ts associated 
with the use of oblimersen in combination with standard 
chemotherapy in the fludarabine-responsive population 
clearly outweighed the risks associated with administration 
of the combination regimen.
Role of oblimersen in the treatment 
of CLL
New drugs are needed to treat patients with CLL in both the 
front-line and relapsed/refractory setting. Drugs with novel 
mechanisms of action are particularly desirable given the 
limitations of agents currently used to treat this malignancy. 
The phosphorothioate oligonucleotide oblimersen is particu-
larly well designed for the treatment of patients with CLL, 
having been engineered to prevent translation of the Bcl-2 
protein that is associated with both the pathogenesis of CLL 
and resistance to chemotherapy.
Uptake of oblimersen into patient cells with subsequent 
decreases in bcl-2 RNA and Bcl-2 protein has been docu-
mented in patients with acute myeloid leukemia (Marcucci 
et al 2005), but has not yet been assessed in patients with 
CLL. Results suggest a correlation between clinical outcome 
and the antisense activity of oblimersen as measured by bcl-2 
mRNA downregulation and Bcl-2 protein levels.
The 3 clinical studies of oblimersen in CLL conﬁ  rm 
that oblimersen is an effective therapeutic agent in this 
disease. Results of the Phase III trial, the only randomized 
comparative study in CLL to date, are especially compelling 
and include a statistically signiﬁ  cant increase in the rate of 
complete and nodular partial responses. These responses 
were durable and highly correlated with time to progression, 
survival, and duration of symptomatic relief (P   0.0001) and 
afford patients true clinical beneﬁ  t. The addition of oblim-
ersen to ﬂ  udarabine/cyclophosphamide therapy signiﬁ  cantly 
increased the rate of complete and nodular partial responses 
from 7% (with standard chemotherapy) to 17%. In the popu-
lation of patients who remained sensitive to ﬂ  udarabine, the 
difference was much greater (6% versus 25%, respectively), 
and survival clearly indicated a beneﬁ  cial, statistically sig-
niﬁ  cant effect with the oblimersen plus Flu/Cy regimen. As 
cytogenetic data were not required for entry in this study, 
the efﬁ  cacy of oblimersen in high-risk patients with CLL has 
yet to be documented.
Although the response rates achieved in the Phase III 
study were lower than those reported in the literature with 
ﬂ  udarabine/cyclophosphamide alone (Wierda et al 2006), 
important differences in this study include the multicenter 
study design, central determination of hematologic and clini-
cal response, heavily pretreated patient population, and the 
requirement for re-imaging by CT/ultrasound to determine 
response in patients with abnormalities identiﬁ  ed at baseline 
by these radiographic methods (O’Brien et al 2007). Such 
Table 7 Comparison of key safety ﬁ  ndings: Phase III study, all treated patients and ﬂ  udarabine-relapsed treated patients
  Oblimersen plus   Flu/Cy  P 
 Flu/Cy  %  value
 % 
All treated patients  N = 115  N = 115 
Grade 3–4 adverse events     
 Thrombocytopenia  33  20  0.03
 Neutropenia  19  24  NS
 Anemia  15  15  NS
Treatment-related discontinuations due to   25  24  NS
adverse events     
Treatment-related deaths  4  2  NS
Fludarabine-relapsed treated patients  N = 47  N = 49 
Grade 3–4 adverse events     
 Thrombocytopenia  32  22  NS
 Neutropenia  13  31  0.03
 Anemia    4  18  0.03
Treatment-related discontinuations due to   30  27  NS
adverse events     
Treatment-related deaths  0  4  NS
Abbreviations: Flu/Cy, ﬂ  udarabine/cyclophosphamide; NS, not signiﬁ  cant.
(data on ﬁ  le, Genta Incorporated).Therapeutics and Clinical Risk Management 2007:3(5) 869
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radiographic imaging has been shown to reduce the response 
rate by approximately one third (Eichhorst et al 2006).
Although a complete or nodular partial response was 
achieved in some patients refractory to fludarabine, a 
disproportionately greater number of responding patients 
were those who remained sensitive to this agent, that is, the 
relapsed patient population. This ﬁ  nding is consistent with 
the chemosensitizing effect of oblimersen and was similarly 
evident in the Phase II trial conducted in previously treated 
and previously untreated patients.
Considering current CLL therapies, the addition of oblim-
ersen to chemotherapy raises no new safety concerns. Several 
ﬁ  ndings that occurred most often during the ﬁ  rst treatment 
cycle – thrombocytopenia and, rarely, infusion reactions – are 
similarly reported with available therapies, familiar to the 
oncologist, and managed by careful patient monitoring and 
scrupulous attention to the patient’s hydration status. The 
increased incidence of catheter-related complications associ-
ated with the current route of administration for oblimersen 
may be eliminated if other routes of administration for 
oblimersen currently under clinical evaluation (subcutaneous 
injection, short intravenous infusion) prove effective.
Oblimersen is a promising new agent that may add to the 
efﬁ  cacy of other treatments in the management of patients 
with CLL. Further study in the untreated CLL popula-
tion is warranted, particularly in patients with high-risk 
cytogenetic factors, and continued study in other hemato-
logic malignancies, particularly those of B-cell origin, is 
appropriate.
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